Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy

BACKGROUND: Rolapitant, a novel neurokinin‐1 receptor antagonist, provided effective protection against chemotherapy‐induced nausea and vomiting (CINV) in a randomized, double‐blind phase 3 trial of patients receiving moderately emetogenic chemotherapy or an anthracycline and cyclophosphamide regime...

Descripción completa

Detalles Bibliográficos
Autores principales: Hesketh, Paul J., Schnadig, Ian D., Schwartzberg, Lee S., Modiano, Manuel R., Jordan, Karin, Arora, Sujata, Powers, Dan, Aapro, Matti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084806/
https://www.ncbi.nlm.nih.gov/pubmed/27176138
http://dx.doi.org/10.1002/cncr.30054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084806/
https://www.ncbi.nlm.nih.gov/pubmed/27176138
http://dx.doi.org/10.1002/cncr.30054

Ejemplares similares